{
  "paper_id": "4fd25cc19b106e5c8a69f89162ca37719192330d",
  "metadata": {
    "title": "Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) †",
    "coda_data_split": "train",
    "coda_paper_id": 10311,
    "coda_has_expert_labels": false,
    "subset": "noncomm_use_subset"
  },
  "abstract": [
    {
      "original_text": "untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247. 17. Karthaus M, Schwartzberg L, Rivera F et al. Updated overall survival (OS) analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK: A 1st-line phase 2 study of FOLFOX6 plus panitumumab ( pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). Eur J Cancer 2013; 49: S516. 18. Ciardiello F, Lenz HJ, Kohne CH et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014; 32: abstr 3506. 19. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634. 20. Jonker DJ, O\u0027Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048. 21. Venook AP, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients ( pts) with KRAS wild-type",
      "sentences": [
        [
          {
            "segment_text": "untreated , unresectable , wild-type KRAS exon 2 metastatic colorectal cancer .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "J Clin Oncol 2014 ; 32 : 2240-2247 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "17 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Karthaus M , Schwartzberg L , Rivera F et al. .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Updated overall survival ( OS ) analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK : A 1st-line phase 2 study of FOLFOX6 plus panitumumab ( pmab ) or bevacizumab ( bev ) in metastatic colorectal cancer ( mCRC ) .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Eur J Cancer 2013 ; 49 : S516 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "18 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Ciardiello F , Lenz HJ , Kohne CH et al. .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer ( mCRC ) randomized to FOLFIRI with/without cetuximab .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "J Clin Oncol 2014 ; 32 : abstr 3506 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "19 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Amado RG , Wolf M , Peeters M et al. .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "J Clin Oncol 2008 ; 26 : 1626-1634 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "20 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Jonker DJ , O\u0027Callaghan CJ , Karapetis CS et al. .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Cetuximab for the treatment of colorectal cancer .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "N Engl J Med 2007 ; 357 : 2040-2048 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "21 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Venook AP , Niedzwiecki D , Lenz HJ et al. .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "CALGB/SWOG 80405 : Phase III trial of irinotecan/5-FU/leucovorin ( FOLFIRI ) or oxaliplatin/5-FU/leucovorin ( mFOLFOX6 ) with bevacizumab ( BV ) or cetuximab ( CET ) for patients ( pts ) with KRAS wild-type",
            "crowd_label": "background"
          }
        ]
      ]
    },
    {
      "original_text": "Up to 25% of patients with profound neutropenia lasting for \u003e10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. † This manuscript does not refer to patients undergoing allogeneic hematopoietic stem cell transplantation. These patients are subject to a separate AGIHO guideline [1] .",
      "sentences": [
        [
          {
            "segment_text": "Up to 25 % of patients with profound neutropenia lasting for \u003e 10 days develop lung infiltrates ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "which frequently do not respond to broad-spectrum antibacterial therapy .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "While a causative pathogen remains undetected in the majority of cases ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "Aspergillus spp. , Pneumocystis jirovecii ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "multi-resistant Gram-negative pathogens , mycobacteria or respiratory viruses may be involved .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "In at-risk patients who have received trimethoprim-sulfamethoxazole ( TMP/SMX ) prophylaxis ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "filamentous fungal pathogens appear to be predominant ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "yet commonly not proven at the time of treatment initiation .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "† This manuscript does not refer to patients undergoing allogeneic hematopoietic stem cell transplantation .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "These patients are subject to a separate AGIHO guideline ( 1 ) .",
            "crowd_label": "finding"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "2",
    "sentence_num": "26",
    "segment_num": "31",
    "token_num": "366"
  }
}